Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 8, 2000, Pages 883-888

  Zimny, M ^a   Fass, J ^a   Bares, R ^a   Cremerius, U ^a   Sabri, O ^a   Buechin, P ^a   Schumpelick, V ^a   Buell, U ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Fluorodeoxyglucose; Pancreatic carcinoma; Positron emission tomography; Prognosis; Standardized uptake value

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033817562     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200750023273     Document Type: Article

References (30)

1. Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater - The prognostic factors influencing the long-term results. A prospective multicentre study
2. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study
3. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors
4. On the origin of cancer cells
5. Quantitating tumor glucose metabolism with FDG and PET
6. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer
7. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases
8. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation
9. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma
10. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography
11. Prediction of survival in glioma patients by means of positron emission tomography
12. 18F-Fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma
13. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
14. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma
15. The applications of PET in clinical oncology
16. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease
17. False-positive FDG PET in patients with pancreatic masses: An issue of proper patient selection?
18. Tumor markers in patients with pancreatic carcinoma
19. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer
20. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma
21. FDG-PET for predicting the prognosis of malignant lymphoma
22. Predicting the prognosis of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose
23. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake
24. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models
25. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors
26. Expression of glucose transporters in head-and-neck tumors
27. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study
28. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival